- This event has passed.
Biotech Commercialization: From Approval to Access (NEW) – October 2025
October 14 @ 9:00 am - October 15 @ 5:00 pm
Members of LabOps Unite, please register here.
Members of Bio CT, please register here.
Please view the discount options for courses before registering here.
-
Member Rate: $1,275
-
Non-Member Rate: $1,500
Interested in offering the training exclusively to a group of your employees? Email courses@massbioed.org to learn more.
Description
This advanced course explores the critical intersection of biotechnology, business, and regulatory frameworks, equipping participants with the knowledge and strategies needed to successfully bring biotech innovations to market. Covering key areas such as regulatory approval pathways, pricing and reimbursement dynamics, market access, and commercialization strategies, this course provides a comprehensive roadmap for navigating the complexities of biotech product launch and market adoption. Through interactive lectures, case studies, and a hands-on capstone project, participants will gain practical insights into market assessment, go-to market planning, strategic partnerships, and financial feasibility.
Date & Time
Tuesday, October 14th, 2025, 9:00 AM – 5:00 PM EST
Wednesday, October 15th, 2025, 9:00 AM – 1:00 PM EST
Please plan to arrive at least 15 minutes before class starts. Class will start at 9:00 AM. We will have breaks in between.
This course will be held in-person. Breakfast and lunch will be provided at this all day workshop.
Agenda
Regulatory Pathways & Market Assessment
- Overview of global regulatory frameworks (FDA, EMA, PMDA, etc.)
- Role of Health Technology Assessment (HTA) bodies in market access
- Market opportunity analysis: TAM, SAM, SOM, and competitive landscape
- Understanding customer needs and decision-making processes
Commercialization & Go-to-Market Strategy
- Developing a commercialization roadmap
- Sales and distribution models for biotech innovations
- Key partnerships, licensing, and business development strategies
- Marketing, branding, and customer engagement for biotech products
Pricing, Reimbursement & Financial Strategy
- Pricing models, reimbursement mechanisms, and value-based agreements
- Clinical indication sequencing and long-term pricing strategy
- Funding mechanisms: venture capital, grants, and partnerships
- Financial feasibility and ROI evaluation for commercialization
Capstone Project: Commercialization Plan & Presentation
- Team-based development of a commercialization plan for a biotech product
- Presentation of strategy, including regulatory approach, financial model, and market entry plan
- Group feedback and expert insights
Instructors
John Tagliamonte
Chief Executive Officer, Mellitus
Business
John Tagliamonte has more than 30 years of experience in executive leadership with responsibility for business development, finance, commercial and business operations, strategic planning, finance and legal functions with established and emerging public and private life sciences companies. As the first Entrepreneur-in-Residence with MassBio, he was responsible for forward-looking program content across the organization, while helping to develop the next generation of biotech entrepreneurs. He currently serves on the business advisory boards of therapeutic startups WntRx, Fractal, MarkTx, PhagePro and Tantu. Previously he led business development at Juniper, was Chief Business Officer of Oxyrane and held various executive business leadership roles at Anchor Therapeutics, ImmunoGen and Johnson & Johnson, as well as venture investing with Safeguard. He began his career as a scientist at Dana-Farber Cancer Institute followed by global business unit management at Bio-Rad. Mr. Tagliamonte received his M.B.A. from Boston College and his B.S. in molecular biology from Tufts University.
Atul Deshpande, Ph.D., MBA
Chief Strategy Officer, Peptilogics
Business
Atul Deshpande is the Chief Strategy Officer at Peptilogics, a clinical stage AI/ML driven peptide therapeutics company, where he is responsible for corporate strategy and business development. Prior to that he was the Chief Executive Officer of IMMEDIATE Therapeutics, a clinical stage biotech company dedicated to developing safe and effective therapeutic solutions to reduce heart muscle damage and prevent cardiac arrest in Acute Coronary Syndromes (ACS), the most common cause of death and morbidity across the world. Atul spent 3 years in China as the Head of Asia Pacific R&D strategy to bring the global portfolio to China with minimal drug lag. Before Sanofi, Atul worked as a management consultant for 9 years on projects across the value chain of pharma. Atul holds a Ph.D. from UC Irvine in Neuroscience and a post-doc from UCLA.